|
|
Neurology September 2009
Volume 73
Issue 12
| This Week in Neurology(R) |
this week in neurology(r): highlights of the september 22 issue.
Pages: 915
|
| Editorials |
the brain and the kidney connection: a model of accelerated vascular cognitive impairment.
- Murray, Anne, MD, MSc. Pages: 916-917
|
what you see depends on how you look: gray matter lesions in multiple sclerosis.
- Chard, Declan, PhD, MRCP, Miller, David, MD, FRCP. Pages: 918-919
|
| Articles |
kidney function is associated with the rate of cognitive decline in the elderly.
- Buchman, A, Tanne, D, Boyle, P, Shah, R, Leurgans, S, Bennett, D. Pages: 920-927
>
Show/Hide Abstract
Objective: We tested the hypothesis that impaired kidney function in the elderly is associated with a more rapid rate of cognitive decline.Methods: Baseline serum was used to calculate estimated glomerular filtration rate (eGFR), using the Modification of Diet in Renal Disease formula, for 886 elderly without dementia participating in the Rush Memory and Aging Project, a prospective, observational cohort study. Kidney function was also dichotomized into impairment or no impairment based on eGFR < or >=60 mL/min/1.73 m2. Structured cognitive testing was performed at baseline and at annual evaluations, using a battery of 19 cognitive tests summarized into global cognition and 5 cognitive domains.Results: In mixed-effects models adjusted for age, sex, and education, a lower eGFR at baseline was associated with a more rapid rate of cognitive decline (estimate 0.0008, SE <0.001, p = 0.017). The increased rate of cognitive decline associated with a 15-mL/min/1.73 m2 lower eGFR at baseline (approximately 1 SD) was similar to the effect of being 3 years older at baseline. Impaired kidney function at baseline was associated with a more rapid rate of cognitive decline (estimate -0.028, SE <0.009, p = 0.003). The increased rate of cognitive decline associated with impaired kidney function at baseline was approximately 75% the effect of ApoE4 allele on the rate of cognitive decline. Baseline kidney function was associated with declines in semantic memory, episodic memory, and working memory but not visuospatial abilities or perceptual speed.Conclusion: Impaired kidney function is associated with a more rapid rate of cognitive decline in old age.(C)2009AAN Enterprises, Inc.
|
declining financial capacity in mild cognitive impairment: a 1-year longitudinal study.
- Triebel, K, Martin, R, Griffith, H, Marceaux, J, Okonkwo, O, Harrell, L, MD, PhD, Clark, D, Brockington, J, Bartolucci, A, Marson, D, JD, PhD. Pages: 928-934
>
Show/Hide Abstract
Objective: To investigate 1-year change in financial capacity in relation to conversion from amnestic mild cognitive impairment (MCI) to dementia.Methods: Seventy-six cognitively healthy older controls, 25 patients with amnestic MCI who converted to Alzheimer-type dementia during the study period (MCI converters), and 62 patients with MCI who did not convert to dementia (MCI nonconverters) were administered the Financial Capacity Instrument (FCI) at baseline and 1-year follow-up. Performance on the FCI domain and global scores was compared within and between groups using multivariate repeated-measures analyses.Results: At baseline, controls performed better than MCI converters and nonconverters on almost all FCI domains and on both FCI total scores. MCI converters performed below nonconverters on domains of financial concepts, cash transactions, bank statement management, and bill payment and on both FCI total scores. At 1-year follow-up, MCI converters showed significantly greater decline than controls and MCI nonconverters for the domain of checkbook management and for both FCI total scores. The domain of bank statement management showed a strong trend. For both the checkbook and bank statement domains, MCI converters showed declines in procedural skills, such as calculating the correct balance in a checkbook register, but not in conceptual understanding of a checkbook or a bank statement.Conclusions: Declining financial skills are detectable in patients with mild cognitive impairment (MCI) in the year before their conversion to Alzheimer disease. Clinicians should proactively monitor patients with MCI for declining financial skills and advise patients and families about appropriate interventions.(C)2009AAN Enterprises, Inc.
|
baseline csf p-tau levels independently predict progression of hippocampal atrophy in alzheimer disease.
- Henneman, W, Vrenken, H, Barnes, J, Sluimer, I, Verwey, N, Blankenstein, M, Klein, M, Fox, N, MD, FRCP, Scheltens, P, MD, PhD, Barkhof, F, MD, PhD, van der Flier, W. Pages: 935-940
>
Show/Hide Abstract
Objective: To investigate whether baseline CSF biomarkers are associated with hippocampal atrophy rate as a measure of disease progression in patients with Alzheimer disease (AD), patients with mild cognitive impairment (MCI), and controls, controlling for baseline neuropsychological and MRI findings.Methods: We assessed data from 31 patients with AD, 25 patients with MCI, and 19 controls (mean age 68 +/- 8 years; 39 [52%] female) who visited our memory clinic and had received serial MRI scanning (scan interval 1.7 +/- 0.7 years). At baseline, CSF biomarkers (amyloid [beta] 1-42, tau, and tau phosphorylated at threonine 181 [p-tau]) were obtained, as well as neuropsychological data. Baseline MRI scans were assessed using visual rating scales for medial temporal lobe atrophy (MTA), global cortical atrophy, and white matter hyperintensities. Hippocampal atrophy rates were estimated using regional nonlinear "fluid" registration of follow-up scan to baseline scan.Results: Stepwise multiple linear regression, adjusted for age and sex, showed that increased CSF p-tau levels ([beta] [standard error]: -0.79 [0.35]) at baseline was independently associated with higher subsequent hippocampal atrophy rates (p < 0.05), together with poorer memory performance (0.09 [0.04]) and more severe MTA (-0.60 [0.21]). The association of memory function with hippocampal atrophy rate was explained by the link with diagnosis, because it disappeared from the model after we additionally corrected for diagnosis.Conclusions: Baseline CSF levels of tau phosphorylated at threonine 181 are independently associated with subsequent disease progression, as reflected by hippocampal atrophy rate. This effect is independent of baseline neuropsychological and MRI predictors. Our results imply that predicting disease progression can best be achieved by combining information from different modalities.(C)2009AAN Enterprises, Inc.
|
in vivo imaging of cortical pathology in multiple sclerosis using ultra-high field mri .
- Mainero, C, MD, PhD, Benner, T, Radding, A, van der Kouwe, A, Jensen, R, Rosen, B, MD, PhD, Kinkel, R. Pages: 941-948
>
Show/Hide Abstract
Objective: We used ultra-high field MRI to visualize cortical lesion types described by neuropathology in 16 patients with multiple sclerosis (MS) compared with 8 age-matched controls; to characterize the contrast properties of cortical lesions including T2*, T2, T1, and phase images; and to investigate the relationship between cortical lesion types and clinical data.Methods: We collected, on a 7-T scanner, 2-dimensional fast low-angle shot (FLASH)-T2*-weighted spoiled gradient-echo, T2-weighted turbo spin-echo (TSE) images (0.33 x 033 x 1 mm3), and a 3-dimensional magnetization-prepared rapid gradient echo.Results: Overall, 199 cortical lesions were detected in patients on both FLASH-T2* and T2-TSE scans. Seven-tesla MRI allowed for characterization of cortical plaques into type I (leukocortical), type II (intracortical), and type III/IV (subpial extending partly or completely through the cortical width) lesions as described histopathologically. Types III and IV were the most frequent type of cortical plaques (50.2%), followed by type I (36.2%) and type II (13.6%) lesions. Each lesion type was more frequent in secondary progressive than in relapsing-remitting MS. This difference, however, was significant only for type III/IV lesions. T2*-weighted images showed the highest, while phase images showed the lowest, contrast-to-noise ratio for all cortical lesion types. In patients, the number of type III/IV lesions was associated with greater disability (p < 0.02 by Spearman test) and older age (p < 0.04 by Spearman test).Conclusions: Seven-tesla MRI detected different histologic cortical lesion types in our small multiple sclerosis (MS) sample, suggesting, if validated in a larger population, that it may prove a valuable tool to assess the contribution of cortical MS pathology to clinical disability.(C)2009AAN Enterprises, Inc.
|
plasma exchange for acute attacks of cns demyelination: predictors of improvement at 6 months.
- Llufriu, S, Castillo, J, Blanco, Y, Ramio-Torrenta, L, Rio, J, Valles, M, Lozano, M, Castella, M, Calabia, J, Horga, A, Graus, F, Montalban, X, Saiz, A. Pages: 949-953
>
Show/Hide Abstract
Background: Plasma exchange (PE) is used to treat severe episodes of CNS demyelination unresponsive to corticosteroids. Predictors of long-term response are not well known.Methods: We retrospectively reviewed the medical records of 41 patients consecutively treated by PE between January 1995 and July 2007. The primary outcome was improvement at 6 months after PE defined as decrease of >=1 point in the Expanded Disability Status Scale (EDSS) score for patients with EDSS <=7.5 or 1.5 points with EDSS >=8.0 or improvement of more than 2 lines in the visual acuity chart for patients with optic neuritis (ON).Results: Twenty-five patients (61%) were women, and the median age was 33 years (range 14-57 years). Twenty-three (56%) had multiple sclerosis, 2 (5%) had clinically isolated syndrome, 2 (5%) had Marburg disease, 7 (17%) had acute disseminated encephalomyelitis, 4 (10%) had neuromyelitis optica, 2 (5%) had idiopathic ON, and 1 (2%) had idiopathic transverse myelitis. The median EDSS score before the attack was 1.0 (range 0-6.5). At PE onset, the median EDSS score was 7.0 (range 3.0-9.5). Sixteen patients (39%) improved at discharge, and 26 (63%) improved at 6 months. In the multivariate analysis, early initiation of PE (odds ratio [OR] 6.29, 95% confidence interval [CI] 1.18-52.96) and improvement at discharge (OR 7.32, 95% CI 1.21-44.38) were significantly associated with response at 6 months.Conclusions: Plasma exchange (PE) was associated with clinical improvement in 63% of patients at 6 months. Early initiation of PE and improvement at discharge were predictors of this response. Twelve patients (48%) who did not improve early did so during follow-up.(C)2009AAN Enterprises, Inc.
|
trends and determinants of end-of-life practices in als in the netherlands.
- Maessen, M, Veldink, J, MD, PhD, Onwuteaka-Philipsen, B, de Vries, J, Wokke, J, MD, PhD, van der Wal, G, MD, PhD, van den Berg, L, MD, PhD. Pages: 954-961
>
Show/Hide Abstract
Background: In the Netherlands, the proportion of patients with amyotrophic lateral sclerosis (ALS) who choose the option of euthanasia or physician-assisted suicide (PAS) is relatively high (20%). The objective of this study was to determine which factors influence end-of-life practices in ALS and whether rates are changing over time.Methods: In a cohort survey, 204 physicians and 198 informal caregivers (response rates 75% and 80%) of patients with ALS who died between 2000 and 2005 filled out questionnaires of the end-of-life circumstances of the patient. Results were compared with those of a similar study performed during the period 1994-1998.Results: In 2000-2005, 16.8% of the patients decided on euthanasia or PAS compared to 20.2% in 1994-1998. Thirty-one (14.8%) patients died during continuous deep sedation (CDS) in 2000-2005. Euthanasia or PAS, but not CDS, were significantly associated with religion not being important to the patient, being more educated, and dying at home. Euthanasia or PAS were not associated with quality of care items or symptoms of depression. Loss of function was similar in both groups. Informal caregivers of patients who died after euthanasia or PAS more frequently reported fear of choking (p = 0.003), no chance of improvement (p = 0.001), loss of dignity (p = 0.02), being dependent on others (p = 0.002), and fatigue (p = 0.018) as reasons for shortening life. Hopelessness was associated with euthanasia or PAS, as with CDS.Conclusion: The frequency of euthanasia or physician-assisted suicide (PAS) in amyotrophic lateral sclerosis (ALS) appeared stable over time and 1 in 7 patients died during CDS. CDS is relatively common in ALS, but appears to have other determinants than euthanasia or PAS. Subjective factors may be important in explaining euthanasia or PAS in ALS.(C)2009AAN Enterprises, Inc.
|
expanding the clinical and neuroradiologic phenotype of primary microcephaly due to aspm mutations.
- Passemard, S, Titomanlio, L, MD, PhD, Elmaleh, M, Afenjar, A, Alessandri, J, Andria, G, MD, PhD, de Villemeur, T, Boespflug-Tanguy, O, MD, PhD, Burglen, L, MD, PhD, Del Giudice, E, Guimiot, F, Hyon, C, Isidor, B, Megarbane, A, Moog, U, MD, PhD, Odent, S, MD, PhD, Hernandez, K, Pouvreau, N, Scala, I, MD, PhD, Schaer, M, MD, PhD, Gressens, P, MD, PhD, Gerard, B, PharmD, PhD, Verloes, A, MD, PhD. Pages: 962-969
>
Show/Hide Abstract
Objective: To determine the spectrum of clinical, neuropsychological, and neuroradiologic features in patients with autosomal recessive primary microcephaly (MCPH) due to ASPM gene mutations.Methods: ASPM was sequenced in 52 unrelated MCPH probands. In patients with ASPM mutations, we evaluated the clinical phenotype, cognition, behavior, brain MRI, and family.Results: We found homozygous or compound heterozygous ASPM loss-of-function mutations in 11 (22%) probands and 5 siblings. The probands harbored 18 different mutations, of which 16 were new. Microcephaly was severe after 1 year of age in all 16 patients, although in 4 patients the occipital-frontal circumference (OFC) at birth was decreased by only 2 SD. The OFC Z score consistently decreased after birth. Late-onset seizures occurred in 3 patients and significant pyramidal tract involvement in 1 patient. Intellectual quotients ranged from borderline-normal to severe mental retardation. Mild motor delay was noted in 7/16 patients. Language development was delayed in all patients older than 3 years. Brain MRI (n = 12) showed a simplified gyral pattern in 9 patients and several malformations including ventricle enlargement (n = 7), partial corpus callosum agenesis (n = 3), mild cerebellar hypoplasia (n = 1), focal cortical dysplasia (n = 1), and unilateral polymicrogyria (n = 1). Non-neurologic abnormalities consisted of short stature (n = 1), idiopathic premature puberty (n = 1), and renal dysplasia (n = 1).Conclusions: We provide a detailed description of features associated with ASPM mutations. Borderline microcephaly at birth, borderline-normal intellectual efficiency, and brain malformations can occur in ASPM-related primary hereditary microcephaly.(C)2009AAN Enterprises, Inc.
|
randomized, controlled trial of telcagepant for the acute treatment of migraine.
- Connor, K, Shapiro, R, MD, PhD, Diener, H, Lucas, S, MD, PhD, Kost, J, Fan, X, Fei, K, Assaid, C, Lines, C, Ho, T. Pages: 970-977
>
Show/Hide Abstract
Background: The neuropeptide calcitonin gene-related peptide (CGRP) plays a key role in migraine pathophysiology. In this large phase 3 clinical trial, we sought to confirm the efficacy of telcagepant, the first orally bioavailable CGRP receptor antagonist.Methods: Adults with migraine with or without aura (International Headache Society criteria) treated a moderate or severe attack with oral telcagepant 50 mg (n = 177), 150 mg (n = 381), 300 mg (n = 371), or placebo (n = 365) in a randomized, double-blind trial. The 5 co-primary endpoints were pain freedom, pain relief, and absence of photophobia, absence of phonophobia, and absence of nausea, all at 2 hours postdose. The key secondary endpoint was 2-24 hour sustained pain freedom. The prespecified primary efficacy analyses evaluated the 150 mg and 300 mg groups; the 50-mg group was included on an exploratory basis to further characterize the dose response but was not prespecified for analysis. Tolerability was assessed by adverse experience reports.Results: Telcagepant 300 mg was more effective (p <= 0.001) than placebo on all primary endpoints and the key secondary endpoint, as was telcagepant 150 mg (p <= 0.05). Telcagepant 300 mg showed a slight numeric advantage over telcagepant 150 mg on most measures. Telcagepant 50 mg values were numerically intermediate between placebo and telcagepant 150 mg and 300 mg. The percentages of patients with adverse experiences were 32.2% for telcagepant 50 mg, 32.0% for telcagepant 150 mg, 36.2% for telcagepant 300 mg, and 32.2% for placebo.Conclusions: This study confirmed previous findings that telcagepant 300 mg was effective at relieving pain and other migraine symptoms at 2 hours and providing sustained pain freedom up to 24 hours. In this study, telcagepant 150 mg was also effective. Telcagepant was generally well tolerated.(C)2009AAN Enterprises, Inc.
|
gray matter changes related to chronic posttraumatic headache.
- Obermann, M, Nebel, K, Schumann, C, Holle, D, Gizewski, E, Maschke, M, Goadsby, P, Diener, H, Katsarava, Z. Pages: 978-983
>
Show/Hide Abstract
Background: Although up to 15% of patients with whiplash injury develop chronic headache, the basis and mechanisms of this posttraumatic headache are not well understood.Methods: Thirty-two patients with posttraumatic headache following whiplash injury were investigated within 14 days after the accident and again after 3 months using magnetic resonance-based voxel-based morphometry. Twelve patients developed chronic headache lasting longer than 3 months and were studied a third time after 1 year.Results: Patients who developed chronic headache revealed decreases in gray matter in the anterior cingulate and dorsolateral prefrontal cortex after 3 months. These changes resolved after 1 year, in parallel to the cessation of headache. The same patients who developed chronic headache showed an increase of gray matter in antinociceptive brainstem centers, thalamus, and cerebellum 1 year after the accident.Conclusion: We demonstrate adaptive gray matter changes of pain processing structures in patients with chronic posttraumatic headache in regard to neuronal plasticity, thus providing a biologically plausible basis for this common, disabling problem.(C)2009AAN Enterprises, Inc.
|
| Views & Reviews |
the present efficacy of multiple sclerosis therapeutics: is the new 66% just the old 33%?
- Klawiter, Eric, Cross, Anne, Naismith, Robert. Pages: 984-990
>
Show/Hide Abstract
A challenge for the clinician treating patients with multiple sclerosis (MS) is to determine the most effective treatment while weighing the benefits and risks. Results of the phase 2 and phase 3 studies on natalizumab were received with great interest, in part due to the "improved" risk reduction for relapse rate, disease progression, and MRI metrics observed in comparison to results in trials of beta-interferon and glatiramer acetate. However, comparison across trials is invalid, in large part due to differences in the study populations. The increased efficacy observed in more recent trials has also been attributed to a fundamental change in subjects with MS enrolled in recent trials compared with the prior decade. In this article, we debate the relative efficacy of natalizumab vs the older injectable therapies.(C)2009AAN Enterprises, Inc.
|
| Clinical/Scientific Notes |
severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.
- Dorr, J, Bitsch, A, Schmailzl, K, Chan, A, von Ahsen, N, Hummel, M, Varon, R, Lill, C, Vogel, H, Zipp, F, Paul, F. Pages: 991-993
|
a patient with episodic ataxia and paramyotonia congenita due to mutations in kcna1 and scn4a.
- Rajakulendran, S, Tan, S, Matthews, E, Tomlinson, S, Labrum, R, Sud, R, Kullmann, D, Schorge, S, Hanna, M. Pages: 993-995
|
| NeuroImages |
weak hands from a flexed neck.
- Dimberg, Elliot, Rubin, Devon. Pages: 996
|
| Resident & Fellow Section |
teaching neuroimages: reversible bilateral thalamic lesions in vein of galen thrombosis.
- Jee, Rou-Chen, Lin, Sheng-Huang, MD, MSc. Pages: e57
|
teaching neuroimages: acute tetraparesis: mind the brain.
- Di Filippo, M, Balucani, C, Parnetti, L, Cardaioli, G, Floridi, P, Calabresi, P. Pages: e58
|
| Correspondence |
autism spectrum disorders following in utero exposure to antiepileptic drugs.
- Evatt, M, DeLong, M, Grant, W, Cannell, J, Tangpricha, V. Pages: 997
|
predictors of poor neurologic outcome after induced mild hypothermia following cardiac arrest.
- Freeman, W, Barrett, K, MD, MSc, Biewend, M, Johnson, M, Divertie, G, Meschia, J. Pages: 997-998
|
education research: assessment of neurology resident clinical competencies in the neurology clinic.
- Gotkine, Marc. Pages: 998-999
|
| Departments: Book Review |
the animal research war.
- Beversdorf, David. Pages: 1000-1001
|
| Departments: Calendar |
calendar.
Pages: 1002-1003
|
| Future Issues |
in the next issue of neurology(r): volume 73, number 13, september 29, 2009.
Pages: A30
|
|
Advertisement
|